Program
Cancer
Types
Phases
Ovarian
Preclinical
Phase l
Phase ll
Phase
lll
Endometrial
Preclinical
Phase l
NHL
Preclinical
Phase l
Phase ll
NHL
Preclinical
Phase l
Phase ll
AML
Preclinical
Phase l
AML
Preclinical
HER2+ mBC 2nd-line
Preclinical
Phase l
Phase ll
Pivotal/
Phase lll
Marketed
HER2+ other
Preclinical
Phase l
Phase ll
Pivotal/
Phase lll
Multiple myeloma
Preclinical
Phase l
Phase ll
Breast, bladder
Preclinical
Phase l
Mesothelioma
Preclinical
Phase l
Phase ll
Multiple myeloma
Preclinical
Phase l
Phase ll
Solid tumors
Preclinical
Phase l
Solid tumors
Preclinical
Phase l
Solid tumors
Preclinical
Phase l
AMG XXX
Undisclosed
Preclinical
Phase l
P-cad+ cancer
Preclinical
Phase l
Solid tumors
Preclinical
Phase l
CX-2009
Undisclosed
Preclinical
TBD
Undisclosed
Preclinical

Earlier stage compounds in development by ImmunoGen and our partners. Amgen, Lilly and Novartis have licences to additional targets.

 ImmunoGen  Roche  Sanofi  Biotest  Bayer  Amgen  Novartis  Lilly  CytomX  Takeda

Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.

* Therapeutic antibody

NHL: non-Hodgkin lymphoma
AML: acute myeloid leukemiam
mBC: metastatic breast cancer
BC: breast cancer

Based on information on clinicaltrials.gov or other public disclosures.


Last updated: June 27, 2016

You are now leaving this website. If you would like to continue, click Continue.
CancelContinue